Anglettere-based medical cannabis producer Dalgety has announced a new distribution agreement with Grow Pharma which will enable the commercial distribution of THC-rich, pharmaceutical-grade prescription medicines to the UK market.
Dalgety’s first product, which obtained a medical cannabis cultivation license earlier this year, is expected to be available by the end of 2023, making it the first cannabis-based medicine grown in the Kingdom -United to be able to be prescribed to patients.
James Leavesley, Chief Operating Officer at Dalgety, said: “We began discussions with Grow over two years ago and share their ambition to be a leader in the medical cannabis industry. From culture to transformation to patient experience, we are aligned in our goal of providing the highest quality medicines and services to patients. I am delighted to announce that this agreement has been brought to fruition.”
The UK medical cannabis market is expected to reach over £1 billion by 2026, helping to drive economic growth in the UK.
Dalgety was founded in 2016 and has since produced several batches of cannabis for commercial purposes.
James Leavesley added: “Over the past five years there has been uncertainty over the cultivation of medical cannabis in the UK, meaning the industry has had to rely solely on imports, a complex process that impacts the consistency of supply of medications prescribed to patients. We are committed to improving patient access to medical cannabis and ensuring they can receive consistent, high-quality medicines, manufactured in a highly regulated environment here in the UK.”
Grow Pharma is one of the UK’s largest distributors of cannabis medicines.
Pierre van Weperen, CEO of Grow Pharma, commented on the transaction: “We have always focused on the needs of the patient, and it is clear that Dalgety has heard and understood this as part of its approach and recognizes the importance of this long-term approach. Our conversations have been focused on this point from the start. Anything that simplifies the UK supply chain and improves its sustainability will make a huge difference to the industry. »
“This is an extremely positive collaboration for Grow, which is able to bring UK-produced medicines with cutting-edge expertise to the pharmaceutical market.
